Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction

Recruiting Phase 3 Interventional Study
Fetal Growth Retardation Stillbirth and Fetal Death Pregnancy Preterm
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Female
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
336 (estimated)
Sponsor
Monash University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Fetal growth restriction (FGR) is a significant health care issue, affecting 20,000 Australian pregnancies every year. Undetected FGR is one of the key risk factors for stillbirth, but FGR can also cause significant impairments in short and long-term health outcomes for the child. It is a major risk factor for preterm birth and is a recognised causal pathway to the neurodevelopmental injury under…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Singleton Pregnancy 2. Severe fetal growth restriction, defined as: * Abdominal circumference ≤3rd centile for gestational age according to charts supplied that have been adapted from Westerway et al; or * Abdominal circumference \<10th centile in combination with at l…
Contacts

Kirsten Palmer, PhD

+61 3 9594 5145

kirsten.palmer@monash.edu

CONTACT